

7 February 2013

SBI Holdings, Inc.

SBI Pharmaceuticals Co., Ltd.

**Notice on the Establishment of Joint Venture Company with Dawani Group Holding,  
Bahrain's Major Corporate Group for Sales of 5-ALA Products**

We are pleased to inform you that SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; "SBI Pharmaceuticals"), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (5-ALA) (\*1) has reached a basic agreement to establish a joint venture company with Dawani Group Holding (head office: Manama, Bahrain; Representative: Abdul Hussain Dawani), Bahrain's major corporate group for sales of 5-ALA products in Bahrain.

Dawani Group Holding is a major distributor and manufacturer which has import companies and companies operating shopping malls in Bahrain under its umbrella. Through the joint venture company which will be established this time, we will proceed with a specific study on 5-ALA product marketing activities in Bahrain. Because Dawani Group Holding is operating its own shopping malls in Bahrain, we are expecting to develop our business at an early stage with regards to sales of 5-ALA products. In addition, SBI Pharmaceuticals will make further efforts to expand sales of 5-ALA products in Middle East regions other than Bahrain in cooperation with Dawani Group Holding, which has know-how in the retail business in the Middle East.

SBI Pharmaceuticals will make every effort to develop businesses through close cooperation with the Bahrain Government, while continuing to explore the various possibilities of 5-ALA and endeavor to conduct R&D jointly with partners in Japan and abroad, aiming to contribute to the health of as many people as possible in the world.

Overview of the joint venture company

Ownership ratio: SBI Pharmaceuticals: 50%, Dawani Group Holding: 50%

Business activities: Marketing and sales of 5-ALA products in the Kingdom of Bahrain

(Details including the trade name and capital will be determined upon conclusion of the joint venture agreement.)

Overview of Dawani Group Holding

Location: P.O. Box 100, Manama, Kingdom of Bahrain.

Representative: Abdul Hussain Dawani

Business activities: Control over group companies engaged in manufacturing, import, retail and/or real estate businesses

URL: <http://www.dawanigroupholding.com>



(\*1) 5-aminolevulinic acid (5-ALA): An amino acid created in mitochondria. It is an important substance that serves as protein material related to energy production in the form of hemes and cytochromes, and its productivity is known to decrease with age. 5-ALA is contained in shochu distillation remnants, red wine and food such as radish sprouts. It is also known as a material forming chloroplasts in plants.

\*\*\*\*\*

For further information, please contact:

SBI Holdings, Inc.: Corporate Communications Dept., Tel: +81 3 6229 0126

SBI Pharmaceuticals Co., Ltd.: Corporate Planning Dept., Tel: +81 3 6229 0095